The FDA has run a sustained, multi-year enforcement campaign against stem cell, PRP, and exosome clinics marketing unapproved HCT/P therapies. The campaign operates primarily through the Center for Biologics Evaluation and Research (CBER) and has produced hundreds of warning letters, several consent decrees, and continued public statements about regenerative medicine marketing. If you run a regen clinic, you should understand how this campaign works - because it is still active, it is expanding into new product categories, and the specific claim patterns it targets are remarkably consistent.
This post breaks down what the campaign actually covers, the specific language patterns the FDA cites most often, how the 361 vs 351 pathway distinction drives enforcement, and a concrete compliance playbook that keeps practices out of the pipeline. We also cover the practical escalation path - what happens between warning letter, untitled letter, and more serious enforcement.
HCT/P - the core regulatory category
HCT/P stands for Human Cells, Tissues, and Cellular and Tissue-Based Products - the FDA’s umbrella category for a range of products that includes the stem cell preparations most regen clinics work with. How an HCT/P is regulated depends on a small set of criteria that collectively determine whether the product can be marketed under the 361 pathway (no pre-market approval required) or the 351 pathway (full drug/biologic approval required).
The 361 pathway criteria
Under 21 CFR Part 1271, an HCT/P qualifies for the 361 pathway if it meets all of the following:
- Minimal manipulation. Processing does not alter the original relevant biological characteristics of the cells or tissue.
- Homologous use. The product performs the same basic function in the recipient that it performed in the donor.
- No combination with another article. Except for specific allowed water, crystalloids, or a sterilizing, preserving, or storage agent.
- Either no systemic effect and not dependent on metabolic activity of living cells, or specific autologous use criteria.The “systemic” prong is where many therapies run into trouble.
Fail any criterion, and the product moves to the 351 pathway - which means it is an unapproved drug or biologic if marketed without pre-market approval.
The specific claim patterns the FDA cites
FDA warning letters in the HCT/P space follow a remarkably consistent template. Reviewing a sample of 20+ letters reveals the same handful of claim categories appearing repeatedly:
Disease-treatment claims
The most commonly cited category. Specific diseases named in marketing - Parkinson’s, multiple sclerosis, Alzheimer’s, ALS, autism, stroke, chronic obstructive pulmonary disease, rheumatoid arthritis, osteoarthritis, heart failure, diabetes, cerebral palsy, traumatic brain injury, spinal cord injury - turn the product’s marketing into drug marketing under 201(g), which immediately flags the product for 351 pathway treatment.
“FDA-approved” misuse
The phrase “FDA-approved” applied to stem cells or HCT/P products is almost always factually wrong. Most HCT/P products are not FDA-approved - they operate under the 361 pathway (no approval needed). Using “FDA-approved” to describe them is both factually incorrect and signals to the FDA that the clinic’s marketing has crossed into drug-promotion territory.
Systemic-effect claims
Claims that a localized HCT/P injection produces systemic effects - “helps with chronic inflammation throughout the body,” “supports immune function generally,” “anti-aging from the inside out” - push the product out of the 361 pathway because systemic effect disqualifies the product from 361 eligibility.
Non-homologous use claims
Using an HCT/P product for a function that is not what it performed in the donor is a homologous-use violation. The most commonly-cited example: using amniotic or placental tissue for joint treatment when the native function of those tissues is not joint-related.
“More than minimal manipulation” signals
Marketing that emphasizes advanced processing - activation, concentration beyond native levels, cell culturing, or combined-product mixing - signals more-than-minimal manipulation, which takes the product out of the 361 pathway. Some of these claims are present to sound impressive to consumers without the clinic realizing they are describing themselves out of 361 status.
Who is actually getting letters
Reviewing the public warning letter database reveals several categories of recipients:
- Solo-owner regen clinics making disease-specific claims. The most common recipient - small practices, often physician-owned, with aggressive marketing that directly claims disease treatment.
- Multi-location franchise operators. Regen clinic franchises where corporate-level marketing was copied to every location, creating widespread exposure to identical claim patterns.
- Tissue bank and processing partners. Labs and tissue suppliers that market directly to clinics, or to patients via clinician partners, with claims the tissue itself cannot legally carry.
- Educational/seminar operations.Businesses that run patient-facing “educational” events where the education is effectively advertising for affiliated clinics’ services.
The enforcement escalation path
FDA HCT/P enforcement typically escalates through a sequence of actions rather than starting with the most severe option. Understanding the path helps clinics interpret the severity of any communication they receive.
Stage 1: Inspection and Form 483 observations
FDA inspections - which are more common at tissue processors and compounding partners than at individual clinics - can produce Form 483 observations flagging specific practices that may violate FDA rules. A 483 is formal but does not yet carry the escalated weight of a warning letter.
Stage 2: Untitled letter
Untitled letters address violations the FDA considers less serious than warning-letter-grade issues. They still require corrective action and should not be dismissed - un-addressed untitled letters frequently escalate to warning letters later.
Stage 3: Warning letter
The main enforcement communication. A warning letter identifies specific violations, gives a typical 15-business-day response window, and requires corrective action. Warning letters are public and searchable.
Stage 4: Consent decree, seizure, or injunction
If warning letters do not produce adequate correction, the FDA can pursue more aggressive action - court-enforced consent decrees, product seizures, and injunctions barring the sale of specific products. These actions are rare in the regen clinic context but have occurred.
Stage 5: Criminal referral
In the most serious cases - typically involving patient harm or continued operation despite enforcement - the FDA can refer matters for criminal prosecution. This is uncommon but has happened in the HCT/P space.
The practical compliance playbook
The clinics that stay clear of this campaign do a few specific things that seem obvious in retrospect but are not, in practice, done consistently across the industry.
Match your marketing language to your regulatory pathway
If you operate under the 361 pathway, your marketing language should match. No disease-treatment claims, no systemic-effect claims, no non-homologous-use claims, no more-than-minimal manipulation language. “May support comfort and function” is compliant; “treats arthritis” is not.
Verify supplier marketing before republishing
Tissue suppliers and device manufacturers often share marketing materials with clinics. Those materials are written for clinician audiences under different rules than consumer marketing. Review every piece of supplier content before re-publishing on your public channels.
Audit staff and physician personal accounts
Physician personal accounts, nurse accounts, and operational staff accounts are all subject to the same rules as the clinic account when they discuss the clinic’s treatments. The FDA reads them together. Audit them together.
Retire legacy testimonials given in old claim contexts
Testimonials collected when the clinic was using aggressive disease-treatment language carry that original context forward if they are republished. If you are rewriting your marketing, retire the legacy testimonials rather than trying to recontextualize them.
Log every claim-related decision
Maintain a compliance file - timestamped records of scan results, legal reviews, and correction decisions. If you ever need to respond to a warning letter, documented compliance-program evidence substantially helps the response.
The FDA does not expect regen clinics to have zero risk. It expects them to have a functioning compliance program that catches most issues most of the time. The difference between a letter-receiving clinic and a non-letter-receiving clinic is typically not perfection - it is the presence of a compliance gate before publish.
Frequently asked questions
Will removing one phrase from my website be enough?
Almost certainly not. FDA warning letters typically cite multiple phrases across multiple surfaces - a single phrase fix may address one cited violation but leave the pattern intact elsewhere. A full audit of every public marketing surface is the only reliable way to address the underlying pattern.
Can I use patient names and photos in before/after content?
Not without HIPAA-compliant authorization, and not with the kind of disease-specific framing the FDA cites in warning letters. Testimonials and before/after content are subject to both HIPAA (for the patient data) and FTC Endorsement Guides (for the marketing claims). HIPAA compliance alone does not cure the marketing-compliance issue.
What if my competitor’s website uses the same claims?
Their exposure is not your protection. “Everyone else does it” is not a defense to an FDA warning letter. Competitors making the same claims increase your urgency to differentiate - your compliance posture becomes a competitive advantage when regulators start the enforcement sweep for your specialty.
Is PRP subject to the same rules as stem cells?
PRP (platelet-rich plasma) is an HCT/P and is subject to the same 361/351 pathway analysis. In practice, PRP marketing faces similar enforcement patterns - disease-specific claims, efficacy guarantees, and off-label-use marketing are the most commonly-cited issues.
What about exosomes specifically?
Exosome marketing has been a particular FDA focus in recent years. Exosome products face specific regulatory scrutiny and the marketing has been a growing enforcement target. Expect continued enforcement attention on exosome claims in 2026.
How do I respond to a warning letter if we receive one?
Call a healthcare regulatory attorney experienced with FDA enforcement the same day you receive it. Do not respond directly without legal counsel. Do not make public statements. Do not delete the cited marketing until you have counsel’s input. The response itself is a complex document with legal implications beyond the immediate correction.